PURPOSE: To evaluate the efficacy and safety of @entity619 ( @entity9170 ) intravitreal implant for the treatment of @entity1103 due to branch @entity2994 . METHODS: We included 22 eyes of 22 @entity1 in this retrospective study. Visual acuity tested in logMAR with Early Treatment @entity6 Study (ETDRS) chart, @entity1020 ( @entity1020 ) measurements, intraocular pressure (IOP), and side effects after treatment were observed monthly. RESULTS: Best corrected visual acuity improved significantly in the first 3 months after the first intravitreal @entity9170 implantation, but no statistically significant change was observed in the following 3 months. Statistically significant improvement was observed in the first 4 months after the second injection of @entity9170 implant, but no statistically significant change was observed in the 2 following months. A statistically significant decrease in @entity1020 was observed in the first 4 months after the first injection, but no statistically significant change was observed in the following 2 months. A statistically significant decrease in @entity1020 was observed in the first 3 months after the second injection, but no statistically significant change was observed in the following 3 months. The IOP could be controlled with medication in all the @entity1 with elevated IOP. Of the @entity1 , 3 had @entity231 requiring surgery. CONCLUSION: Both functional and anatomical effects of @entity9170 implant were obvious in the first 3 months after injection. Repeated injections and frequent examination might be required. Side effects such as @entity231 may require surgical intervention, whereas IOP elevation may be managed by topical drops.

The Efficiency of Intravitreal @entity619 Implants in the Treatment of Macular Edema Secondary to XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity9170 :: ('D003907', 'Chemical') :: ['DEX'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataracts', 'cataract'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness']
@entity2994 :: (MESH:D012170,Disease) :: ['Retinal Vein Occlusion']
